Headquartered in Edmonton, Alberta, Canada, IMBiotechnologies Ltd. is a privately-owned biotechnology company focused on the development and commercialization of medical devices in the area of embolotherapy. The Company’s core technology is designed for the treatment of solid malignant tumors, benign tumors such as uterine fibroids, benign prostatic hyperplasia (“BPH”), and other tissues. IMB’s lead product, Ekobi™ Embolization Microspheres (Trade name “Ekobi™️ EM), is a patented, US FDA cleared, Health Canada approved, “first-in-class” biodegradable embolic therapeutic medical device. Ekobi™ EM is delivered by catheter to the blood vessels that feed a target tissue, where it shuts off the blood supply leading to symptom improvement. Ekobi™ EM is biodegradable (breaks down in the body naturally to carbon dioxide and water) and is detectable by ultrasound.